How big is the Lipid Nanoparticles Market?

The Lipid Nanoparticles Market size is expected to reach USD 0.82 billion in 2024 and grow at a CAGR of 10.54% to reach USD 1.36 billion by 2029. Read More

What is the current Lipid Nanoparticles Market size?

In 2024, the Lipid Nanoparticles Market size is expected to reach USD 0.82 billion. Read More

Who are the key players in Lipid Nanoparticles Market?

Merck KGaA, Arcturus Therapeutics, Inc., Ascendia Pharmaceuticals, Acuitas Therapeutics and Croda International Plc. are the major companies operating in the Lipid Nanoparticles Market. Read More

Which is the fastest growing region in Lipid Nanoparticles Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029). Read More

Which region has the biggest share in Lipid Nanoparticles Market?

In 2024, the North America accounts for the largest market share in Lipid Nanoparticles Market. Read More

What years does this Lipid Nanoparticles Market cover, and what was the market size in 2023?

In 2023, the Lipid Nanoparticles Market size was estimated at USD 0.73 billion. The report covers the Lipid Nanoparticles Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Lipid Nanoparticles Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

Lipid Nanoparticles Market Share

Statistics for the 2023 & 2024 Lipid Nanoparticles market share, created by Mordor Intelligence™ Industry Reports. Lipid Nanoparticles share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

Market Share of Lipid Nanoparticles Industry

The lipid nanoparticles market is semi-consolidated in nature due to the presence of some key players operating globally as well as regionally. The competitive landscape includes an analysis of a few international and local companies that hold considerable market share and are well known. They include Merck KGaA, Croda International PLC, Cytiva, BIOVECTRA, Acuitas Therapeutics, CordenPharma, Genevant Sciences Corporation, Arcturus Therapeutics Inc., Ascendia Pharmaceuticals, and CD Bioparticles.